July 7th 2024
The combination of englumafusp alfa and glofitamab showed a BOR of 67.0% and CR rate of 57.0% in second-line settings. In third-line settings, the BOR was 65.7% and the CR rate was 52.8%.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
How Will New Immunotherapies Fit Into the Treatment Landscape of Follicular Lymphoma?
October 4th 2022Future directions for follicular lymphoma treatments include potential use earlier in treatment or as combination therapy, identifying patients who will benefit most from treatment, and minimizing the costs of therapy while maximizing accessibility.
Read More
CD20/CD3 Bispecific Antibodies Can Revolutionize B-Cell Lymphoma Therapy
October 3rd 2022The bispecific antibodies for B-cell lymphoma that are under development target CD20, and they have a second receptor that targets CD3, which is present on vector T cells, according to Loretta J. Nastoupil, MD.
Read More
Immune Checkpoint Inhibitors and Novel Agents Are Explored in Hodgkin Lymphoma
September 30th 2022As the brentuximab vedotin plus AVD combination gains widespread use, clinicians should recognize the toxicities, such as the risk of neutropenic fever or peripheral neuropathy, according to Alison Moskowitz, MD.
Read More
VITALIZE Trial Explores Maveropepimut-S/Pembrolizumab in Relapsed/Refractory DLBCL
September 15th 2022In an interview with Targeted Oncology, Matthew Matasar, MD, discusses background information on the ongoing VITALIZE trial of maveropepimut-S in patients with diffuse large B-cell lymphoma.
Read More
FDA Lifts Partial Clinical Hold on TakeAim Lymphoma Study of Emavusertib/Ibrutinib
August 19th 2022The TakeAim Lymphoma study will continue to evaluate emavusertib with or without ibrutinib in patients with various types of lymphoma after a 4 1/2-month partial clinical hold placed by the FDA.
Read More
FDA Accepts sBLA for Polatuzumab Vedotin Combination in Previously Untreated DLBCL
August 16th 2022By April 2023, the FDA plans have a decision on the approval application for polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone as an option for treatment-naïve diffuse large B-cell lymphoma.
Read More